Adiponectin inhibits induction of TNF-α/RANKL-stimulated NFATc1 via the AMPK signaling  by Yamaguchi, Noboru et al.
FEBS Letters 582 (2008) 451–456Adiponectin inhibits induction of TNF-a/RANKL-stimulated
NFATc1 via the AMPK signaling
Noboru Yamaguchia,*, Toshio Kukitab, Yin-Ji Lib, Noriaki Kamioc, Satoshi Fukumotoa,
Kazuaki Nonakaa, Yuzo Ninomiyad, Shigemasa Hanazawae, Yoshihisa Yamashitac
a Section of Pediatric Dentistry, Division of Oral Health, Growth and Development, Kyushu University Faculty of Dental Science,
3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan
b Oral Cellular and Molecular Biology, Kyushu University Faculty of Dental Science, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan
c Department of Preventive Dentistry, Kyushu University Faculty of Dental Science, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan
d Section of Oral Neuroscience, Kyushu University Faculty of Dental Science, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan
e Department of Applied Biological Sciences, College of Bioresource Science, Nihon University, Kameino, Fujisawa-City, Kanagawa 292-8510, Japan
Received 31 August 2007; revised 19 December 2007; accepted 22 December 2007
Available online 15 January 2008
Edited by Laszlo NagyAbstract We investigated here whether adiponectin can exhibit
an inhibitory eﬀect on tumor necrosis factor-alpha (TNF-a)- and
receptor activator of nuclear factor-jB ligand (RANKL)-
induced osteoclastogenesis by using RAW264 cell D clone with
a high eﬃciency to form osteoclasts. Globular adiponectin
(gAd) strongly inhibited TNF-a/RANKL-induced diﬀerentiation
of osteoclasts by interfering with TNF receptor-associated factor
6 production and calcium signaling; consequently, the induction
of nuclear factor of activated T cells c1 (NFATc1) was strongly
inhibited. Moreover, we observed that inhibition of AMP-acti-
vated protein kinase abrogated gAd inhibition for TNF-a/
RANKL-induced NFATc1 expression. Our data suggest that
adiponectin acts as a potent regulator of bone resorption
observed in diseases associated with cytokine activation.
 2008 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Adipocytokines [adiponectin, leptin, tumor necrosis factor-
alpha (TNF-a), resistin and so on] play important regulatory
roles in the development or prevention of diabetes [1–3] and
atherosclerosis [4]. Plasma adiponectin concentrations are
inversely correlated with body mass index [5] and are lower
in obese and type 2 diabetes patients [6]. Previous studies have
revealed that a carboxyl-terminal fragment containing the
globular domain of adiponectin (gAd) exists in human plasma.
Fruebis et al. [7] have speculated that the full-length adiponec-
tin circulates in the bloodstream as an inactive precursor of aAbbreviations: AMPK, AMP-activated protein kinase; gAd, globular
adiponectin; MAPK, mitogen-activated protein kinase; NFATc1,
nuclear factor of activated T cells c1; NF-jB, nuclear factor-jB;
TNF-a, tumor necrosis factor-alpha; TRAF6, TNF receptor-associ-
ated factor 6; RANKL, receptor activator of NF-jB ligand
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doi:10.1016/j.febslet.2007.12.037regulatory protein, and they showed that a low level of gAd
exists in human plasma. However, it is reasonable to imagine
that cleavage of adiponectin takes place locally and that the
cleaved product would be abundant in regions of inﬂammation
in light of the following facts: Monocytes/macrophages, neu-
trophils, and leukocyte-derived elastase have been shown to
be involved in acute inﬂammatory responses, such as acute
host defense against microorganisms [8], arthritis [9], and
endotoxin shock [10]. Considering that adiponectin has an
anti-inﬂammatory eﬀect on many types of cells [11,12], it is
possible that this eﬀect is modulated positively by the cleavage
of adiponectin by leukocyte elastase [13].
Osteoclasts are multinucleated giant cells that resorb bone
and originate from hemopoietic progenitors of the monocyte/
macrophage lineage. Receptor activator of NF-jB ligand
(RANKL) is a member of the TNF-ligand family essential
for the induction of osteoclastogenesis [14,15]. A recent study
[16] revealed that adiponectin is able to inhibit RANKL-
induced osteoclast diﬀerentiation. However, the inhibitory
mechanism of the cytokine has not been demonstrated at the
molecular level. Therefore, we were interested in deﬁning the
target molecule of adiponectin in RANK signaling of osteo-
clasts. Interestingly, Takayanagi [17] recently found nuclear
factor of activated T cells c1 (NFATc1) to be the master tran-
scriptional factor of RANKL-induced osteoclastogenesis.
Thus, to explore whether NFATc1 is a target molecule of
adiponectin in TNF-a/RANKL-induced osteoclast formation,
in this study, we used RAW264 cell D clone (D clone), which
has a high ability to form osteoclasts, to determine whether
gAd is able to inhibit TNF-a/RANKL-induced osteoclasto-
genesis by acting as a potent negative regulator of NFATc1.
And, we suggest herein that adiponectin acts as a potential neg-
ative regulator of TNF-a/RANKL-induced osteoclastogenesis
via inhibiting NFATc1 expression and also that the inhibitory
signal is mediated by AMP-activated protein kinase (AMPK).
2. Materials and methods
2.1. Reagents
Glutathione S-transferase fusion vector [pGEX-6P-1 (GE Health-
care Bio-Sciences Corps., Piscataway, NJ, USA)] containing the glob-
ular domain of mouse 30-kDa adipocyte complement-related protein
was provided by Dr. I. Shimomura (Osaka University, Osaka, Japan).
Recombinant gAd was prepared as described previously [12].blished by Elsevier B.V. All rights reserved.
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BioVision Inc. (Mountain View, CA, USA). Tartrate-resistant acid
phosphatase (TRAP) staining kit and ionomycin were supplied by Sig-
ma–Aldrich Corp. (St. Louis, MO, USA). Soluble RANKL and TNF-
a were obtained from PeproTech EC (London, UK). AMPK inhibitor
(compound C) and p38 mitogen-activated protein kinase (MAPK)
inhibitor (SB203580) were purchased from Calbiochem Corp. (San
Diego, CA, USA). Rabbit anti-mouse AdipoR1 antibody and rabbit
anti-mouse AdipoR2 antibody were obtained from Alpha Diagnostic
International (San Antonio, TX, USA).
2.2. Culture conditions for forming osteoclast-like multinucleated cells
from D clone
The D clone was established and characterized as described previ-
ously [18]. The cells were cultured in a-modiﬁed Eagles medium (a-
MEM) containing 10% fetal bovine serum (6.8 · 103 cells in 150 ll/well
for 96-well plates) for 3 days in the presence of 2.5–20 lg/ml adiponec-
tin and 20 ng/ml soluble RANKL with 1 ng/ml TNF-a [18]. Cultures
were maintained at 37 C under 5% CO2.
2.3. Western blotting
Whole-cell lysates (20 lg of protein) were resolved on 12.5% SDS–
PAGE gels, and then electrophoretically transferred to nitrocellulose
membranes. Immunoblotting was performed as described previously
[12]. The membranes were ﬁrst exposed to primary antibodies, and
then to secondary antibodies conjugated with horseradish peroxidase.
The primary antibodies used were anti-NFATc1 antibody (7A6), anti-
TNF receptor-associated factor 6 (TRAF6) antibody (H-274), and
anti-c-Fos antibody (H-125) (Santa Cruz Biotechnology, Santa Cruz,
CA, USA), and anti-actin antibody (MP Biomedicals Inc., Aurora,
OH, USA).
2.4. Ca2+ measurement
The D clone cells were incubated with 20 ng/ml RANKL and 1 ng/
ml TNF-a in the presence or absence of 20 lg/ml gAd for 24 h. For
Ca2+ measurement, the cells were incubated in the presence of 5 lMFig. 1. Morphological demonstration of gAd inhibition of TNF-a/RANKL-i
clone was cultured for 3 days in the absence of 1 ng/ml TNF-a and 20 ng/ml R
diﬀerentiated into TRAP-positive MNCs in the presence of these stimulants.
TRAP-positive MNCs under these conditions (C). DI gAd did not inhibit Tﬂuo-4 AM (Molecular Probes, Inc., Eugene, OR, USA) for 30 min
in serum-free a-MEM. They were then washed twice with Hanks
balanced salt solution, after which intracellular Ca2+ levels were
monitored by using an AQUA COSMOS Ca2+ imaging system
(Hamamatsu Photonics, Hamamatsu, Japan). The increase in the ﬂuo-
rescence of ﬂuo-4 AM from the basal level was divided by the maxi-
mum increase (obtained by adding 10 lM ionomycin), and expressed
as a decimal percent of the maximum increase.2.5. Statistical analysis
Students t-test was used to determine the statistical signiﬁcance of
diﬀerences between results obtained for the adiponectin-untreated
group versus those from the adiponectin-treated groups, and between
results obtained for the inhibitor-unpretreated group versus those from
the inhibitor-pretreated groups.3. Results
3.1. Adiponectin inhibition of TNF-a/RANKL-induced
osteoclast formation from RAW264 D clone via AdipoR1
We previously isolated the D clone, which showed a high
eﬃciency to form osteoclasts from RAW264 cells [18]. Using
this clone, we examined the eﬀect of gAd on the TNF-a/
RANKL-induced formation of TRAP-positive multinucleated
cells (MNCs). As shown in Figs. 1 and 2A, although gAd (2.5–
20 lg/ml) strongly inhibited TNF-a/RANKL-induced forma-
tion of osteoclast-like MNCs from the D clone cells, no
inhibitory eﬀect was observed when cultures were treated with
heat-inactivated (100 C for 10 min) gAd (DI gAd)-treated
cultures (Figs. 1D and 2A). On the other hand, fAd (2.5–
20 lg/ml) also signiﬁcantly inhibited TNF-a/RANKL-inducednduced osteoclast formation from cells of the RAW264 D clone. The D
ANKL (A), or in the presence of both of them (B). The cells eﬃciently
On the other hand, gAd (20 lg/ml) strongly inhibited the formation of
NF-a/RANKL-induced osteoclastogenesis (D). Scale bar, 60 lm.
Fig. 2. Inhibitory eﬀect of adiponectin on TNF-a/RANKL-induced osteoclast formation by D clone. Cells were cultured in 96-multiwell culture
plates for forming osteoclast-like MNCs in the presence of 1 ng/ml TNF-a, 20 ng/ml RANKL. When various concentrations of gAd (A) or fAd (B)
were added to these cultures, both gAd and fAd markedly inhibited the formation of TRAP-positive MNCs in a dose-dependent manner. Both DI
gAd and DI fAd did not inhibit TNF-a/RANKL-induced osteoclastogenesis. (C) Diﬀerentiation-stage dependence of the eﬀect of gAd. The addition
of gAd (20 lg/ml) at the early stage (0–12 h) completely inhibited the osteoclastogenesis evaluated at 72 h, but the addition of it at the late stage (12–
72 h) had no eﬀect. (D) Anti-AdipoR1 antibody blocks gAd-mediated inhibition of TNF-a/RANKL-induced osteoclast formation. The D clone cells
were pretreated or not with 10 lg/ml of normal rabbit IgG, 10 lg/ml of anti-AdipoR1 antibody, or 10 lg/ml of anti-AdipoR2 antibody for 1 h at 37
C, and then treated for 3 days with or without 20 lg/ml gAd, 1 ng/ml TNF-a and 20 ng/ml RANKL. Then, TNF-a/RANKL-induced osteoclast
formation was measured as described in ‘‘Materials and methods’’. Values signiﬁcantly diﬀerent from the values for the normal rabbit IgG and gAd-
treated group or the gAd only-pretreated group are indicated. These data represent typical results from three independent experiments. *P < 0.001.
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well as gAd (Fig. 2B).
Since it was of interest to us to examine at what stage of
osteoclast formation gAd acted, we examined this point by
adding gAd at various times to TNF-a/RANKL-stimulated
cultures. The formation of TRAP-positive MNCs was almost
completely inhibited when such cultures were treated with
gAd at an early stage (between 0 and 12 h after TNF-a/
RANKL stimulation), whereas such inhibition was not ob-
served when gAd was added 12 h after TNF-a/RANKL stim-
ulation (Fig. 2C). These results suggest that gAd suppressed
cellular events activated by TNF-a/RANKL at an early stage
of osteoclast diﬀerentiation.
Moreover, we explored which receptor is involved in the
gAd-mediated inhibition of TNF-a/RANKL-induced osteo-clastogenesis. As shown in Fig. 2D, although anti-AdipoR1
antibody signiﬁcantly blocked the inhibitory eﬀect of gAd,
such signiﬁcant inhibition was not observed with anti-Adi-
poR2 antibody. This result suggests that gAd inhibition of
TNF-a/RANKL-induced osteoclastogenesis is predominantly
mediated via AdipoR1.
3.2. gAd inhibition of TNF-a/RANKL-induced NFATc1
activation
As described above, since we demonstrated that adiponectin
was a potent negative regulator of TNF-a/RANKL-mediated
osteoclast formation, we next investigated the mechanism by
which gAd interferes with the intracellular signaling pathways
activated by TNF-a/RANKL. RANKL binding to its receptor
RANK results in the recruitment of TRAF family proteins
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(NF-jB), MAPK, and Akt pathways [19,20]. Also, RANKL
selectively induces the NFATc1 gene in a TRAF6- and c-
Fos-dependent fashion [21]. Therefore we hypothesized as a
possible mechanism that gAd inhibits TNF-a/RANKL-medi-
ated osteoclast formation by inhibiting NFATc1 expression.
In testing this possibility, we found, as shown in Fig. 3A,
that gAd strongly inhibited the TNF-a/RANKL-induced
expression of NFATc1 protein in a dose-dependent manner.
In contrast, DI gAd was not inhibitory (data not shown). In
addition, we also observed that gAd was able to block the
induction of TRAF6 protein, but not that of c-Fos protein
(Fig. 3B).
3.3. Eﬀect of gAd on RANKL-stimulated NFATc1 induction
pathway
It has been shown that RANKL-induced Ca2+ oscillation is
essential for the autoampliﬁcation of the NFATc1 gene expres-
sion that is critical for sustained NFATc1-dependent transcrip-
tion [21]. Therefore, we investigated the action of gAd on Ca2+
signaling in the D clone cells stimulated with TNF-a/RANKL.
As shown in Fig. 4, importantly, gAd inhibited RANKL-
induced Ca2+ oscillation, suggesting that the inhibition of
RANKL-induced Ca2+ signaling could account for the inhibi-Fig. 4. Eﬀect of gAd on TNF-a/RANKL-induced Ca2+ signaling in the D c
RANKL in the absence (A) or presence (B) of gAd for 24 h are shown. The i
by the maximum increase and expressed as a decimal percent plotted at 1-s in
addition of 10 lM ionomycin at the end of each experiment, as indicated by
reveals the oscillation of [Ca2+]i in TNF-a/RANKL-treated cells.
Fig. 3. Eﬀect of gAd on the expression of essential mediators of TNF-a/RAN
gAd inhibited TNF-a/RANKL-induced NFATc1 production in a dose-depe
NFATc1 and TRAF6 production at an early stage. In contrast, the gAd
examined.tion of NFATc1 expression by gAd. Although the data are not
shown, DI gAd did not aﬀect RANKL-induced Ca2+ oscilla-
tion.
3.4. gAd inhibition of TNF-a/RANKL-induced NFATc1
expression is dependent on AMPK activation
Several downstream mediators of adiponectin signaling have
been demonstrated in several diﬀerent cell types. In the liver
and skeletal muscle, adiponectin is known to activate AMPK
[3,22,23] and p38 MAPK [22,24]. Therefore, using a potent
inhibitor of AMPK or p38 kinase, ﬁnally, we investigated
whether AMPK activation or p38 activation plays a functional
role in adiponectin inhibition for TNF-a/RANKL-induced
osteoclast formation and NFATc1 expression. We pretreated
the D clone cells with or without compound C, an AMPK
inhibitor, or SB203580, a p38 kinase inhibitor, for 1 h prior
to gAd treatment. Consequently, we observed that gAd inhibi-
tion for TNF-a/RANKL-induced osteoclast formation and
NFATc1 expression was signiﬁcantly canceled when the cells
were pretreated with compound C, but not with SB203580
(Fig. 5A and B). These results suggest a possibility that AMPK
plays a functional role in the inhibitory action of gAd on TNF-
a/RANKL-induced osteoclast formation and NFATc1 expres-
sion.lone. The traces of [Ca2+]i changes in single cells treated with TNF-a/
ncrease in the ﬂuorescence of ﬂuo-4 AM from the baseline was divided
tervals. The maximum increase in the ﬂuorescence was obtained by the
the arrow. Each color indicates a diﬀerent cell in the same ﬁeld, and
KL signaling. (A) NFATc1 was markedly induced by TNF-a/RANKL.
ndent fashion. (B) gAd remarkably inhibited TNF-a/RANKL-induced
treatment had little eﬀect on c-Fos production over the time course
Fig. 5. Involvement of AMPK in gAd inhibition of TNF-a/RANKL-
induced osteoclast formation and NFATc1 expression. (A) The D
clone cells were pretreated or not for 1 h with dimethylsulfoxide
(DMSO; control), compound C (10 lM) or SB203580 (10 lM) and
then treated for 3 days with or without 20 lg/ml gAd, 1 ng/ml TNF-a
and 20 ng/ml RANKL. Then, TNF-a/RANKL-induced osteoclast
formation was measured as described in ‘‘Materials and methods’’.
*P < 0.001. (B) The cells were pretreated or not for 1 h with DMSO
(control), compound C (10 lM) or SB203580 (10 lM) and then treated
for 24 h with or without 20 lg/ml gAd, 1 ng/ml TNF-a and 20 ng/ml
RANKL, and lysed for Western blotting. Relative band intensities
were determined by using image analyzer. The values below the bands
are the mean fold increase in the expression levels of the D clone cells
treated with several reagents compared with that of untreated cells.
The experiments were performed three times, and similar results were
obtained independently in each experiment.
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We demonstrated herein that gAd was strongly able to block
TNF-a/RANKL-induced NFATc1 activation (Fig. 3). Since
the transcription factor NFATc1 has been identiﬁed as the
master switch regulator of osteoclastogenesis [17], the present
study suggests that adiponectin plays an important role as a
potent negative regulator of osteoclastogenesis. Our previous
study showed that gAd also inhibits the Toll-like receptor
family (TLR)-induced NF-jB signaling pathway [12]. Interest-
ingly, Takatsuna et al. [25] recently demonstrated that NF-jB
activation is an important event in RANKL-mediated induc-
tion of NFATc1 at the early phase of osteoclastogenesis. Since
it has also been shown that both NF-jB and AP-1 binding
sites are localized within the promoter region of the NFATc1
gene [26], it was very important for us to demonstrate that
adiponectin inhibition of TNF-a/RANKL-induced NFATc1
activation resulted from its inhibition of NF-jB activation.TRAF6 is a key molecule in TNF-a/RANKL-induced NF-
jB signaling. Therefore, we examined whether adiponectin
could inhibit TRAF6 expression. We observed that the gAd
addition at a late stage inhibited TNF-a/RANKL-induced
TRAF6 expression at the protein level (Fig. 3B). These obser-
vations suggest to us the possibility that adiponectin regulates
TNF-a/RANKL-induced expression of NFATc1 by inhibiting
TRAF6-dependent NF-jB signaling.
On the other hand, calcium signal-mediated activation of
NFATc1 triggers the autoampliﬁcation loop of NFATc1
and ensures a sustained NFATc1-dependent transcriptional
program [21,27]. The mechanism by which RANKL stimula-
tion results in Ca2+ oscillation is currently unknown [28].
However, it is clear that the Ca2+/calcineurin pathway is
an essential pathway associated with RANKL signaling
[21]. The sustained activation of NFATc1, mediated by a
low-level Ca2+ oscillation, may be necessary during the en-
tire process of osteoclast diﬀerentiation. Therefore, it is very
important to investigate whether Ca2+ oscillation is also an-
other target in adiponectin inhibition of RANKL-induced
NFATc1. Interestingly, we observed an inhibitory action
of gAd on RANKL-induced oscillation. These observations
suggest the possibility that Ca2+ oscillation may also be in-
volved in gAd inhibition of RANKL-induced NFATc1 acti-
vation.
We previously showed that gAd suppresses TLR-induced
NF-jB activation through AdipoR1 in RAW264 cells [12].
In addition, we observed that gAd inhibition of TNF-a/
RANKL-induced osteoclastogenesis is predominantly medi-
ated via AdipoR1 (Fig. 2D). Interestingly, a recent study
has shown that AdipoR1 is more tightly linked to the acti-
vation of the AMPK pathway [29], Therefore, we investi-
gated whether activation of AMPK and p38 kinase plays
an important role in inhibitory action of gAd on TNF-a/
RANKL-induced NFATc1 expression. Since the gAd inhibi-
tion was blocked when the D cell clone was pretreated with
an AMPK inhibitor, but not with a p38 kinase inhibitor,
AMPK activation may be required for the gAd inhibitory
signal of TNF-a/RANKL-induced NFATc1 activation.
However, each inhibitor did not work on the abrogation
of the inhibition of Ca2+ oscillation by gAd (data not
shown).
Taken together, our present study suggests that adiponectin
plays an important role as a negative regulator of RANKL-
mediated osteoclast diﬀerentiation by acting as an inhi-
bitor of NFATc1 activation through the AMPK signaling
pathway.
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